Data collection
death, CRC, ALRI, AJCC, Cancer
METASTASIS, RECURRENCE, PRIMARY TUMOR, BLOOD, CANCER
Patients’ demographic and clinicopathological features were obtained from retrospective medical records. The pathological staging of patients was defined using both the traditional TNM staging and the American Joint Committee on Cancer (AJCC) staging, respectively. Data on lactate dehydrogenase, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, platelet, lymphocyte, and neutrophil were extracted from the results of the first blood routine tests and biochemical tests (limit to 30 days prior to surgery). Blood routine tests and biochemical tests were based on a single blood sample of each patient and were measured by auto analyzers.The De Ritis ratio, aspartate aminotransferase-to-platelet ratio index (APRI), aspartate aminotransferase-to-lymphocyte ratio index (ALRI), aspartate aminotransferase-to-neutrophil ratio index (ANRI), and alkaline phosphatase-to-platelet ratio index (APPRI) were calculated using the following formulas: De Ritis ratio = aspartate aminotransferase level (U/L)/alanine aminotransferase level (U/L) [Patients were followed up regularly according to NCCN guidelines. The last time of follow-up was January 22, 2019. The survival information was obtained from contacts with patients by phone. Overall survival (OS) was defined as the period from surgery to death from any cause, or the last contact. Disease-free survival (DFS) was defined as the period from surgery to local recurrence, distant metastasis, a new primary tumor of CRC, or death, whichever comes first.